Single-Dose Intravesical Chemotherapy After Diagnostic URS

Bladder Cancer Clinical Trial

— MINERVA  

Official title:

Single-Dose Intravesical Instillation of Chemotherapy After Diagnostic/Therapeutic Flexible Ureteroscopy for Upper Tract Urothelial Carcinoma in the Prevention of Intravesical Recurrence: Prospective Randomized Multicenter Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05810623
• Other study ID #: 2411-2021
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 1, 2023
• Est. completion date: December 31, 2026

Study information

• Verified date: March 2023
• Source: Medical University of Vienna
• Contact: Shahrokh F Shariat, MD, Prof
• Phone: +4314040026150
• Email: shahrokh.shariat[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study design This study is a Phase III, randomized, open-label, multi-center, global study to determine the efficacy of a single immediate intravesical chemotherapy instillation (SI) in the prophylaxis of intravesical recurrence after diagnostic uretero-renoscopy (URS) of patients 18 years of age or older with the fist diagnosis of UTUC.

This study will randomize 394 patients globally Patients will be randomized in a 1:1 ratio to the interventional arm or to observation.

Study period This study will include a screening period, a treatment and disease assessment period, safety follow-up visits and a 5-year survival follow-up period to begin immediately after the treatment.

Screening period: The period up to 28 days prior to intervention during which the screening procedures occur.

Treatment and disease assessment period: The period starting the day of diagnostic URS (Day 0) during which patients receive their assigned treatment (Day 0 to day 1) and disease assessments are performed. All patients must follow the disease assessment schedule, which includes disease assessments at screening and every 3 months (±1 week) from the date of intervention until 24 months from the date of randomization, and then every 6 months for up to 5 years. The treatment and disease assessment period will end at the time of intravesical recurrence, death, or MINERVA-CTU decision to terminate the trial early.

Safety follow-up visits: Every patient in this study will be assessed for the occurrence of adverse events (AEs) and serious adverse events from the time of signed informed consent until 90 days after the administration of SI. All patients who receive SI will have safety visits 4, 8, and 12 weeks following administration of SI. Safety assessments include targeted physical examination, complications according to Dindo-Clavien classification and patient-reported outcomes (PRO) assessments.

Survival follow-up period: Patients will be followed up at in-clinic site visits, by telephone contact, or by contact with the patient's current physician for up to 5 years from the date of randomized into this study.

Objectives Primary objective Efficacy of a SI in the prophylaxis of intravesical recurrence after diagnostic URS for UTUC

Secondary objectives

• Time to intravesical recurrence

• 5-years intravesical recurrence rates

• Incidence of high-grade BCa recurrence

• Incidence and gravity of adverse events (AEs) due to the SI

• To collect and store blood, urine and tissue samples according to each country's local and ethical procedures for identifying candidate markers that may correlate with likelihood of clinical benefit (optional)

• To collect and store DNA according to each country's local and ethical procedures for future exploratory research into somatic mutations and genes/genetic variations that may influence oncologic outcomes, to study treatments and susceptibility to disease (optional)

• To assess disease-related symptoms and HRQoL in patients with UTUC treated with SI compared those undergoing observation

• To assess patient-reported treatment tolerability directly using specific PRO-CTCAE symptoms

Target study population The study population includes patients 18 years of age or older with a primary diagnosis of UTUC, scheduled for diagnostic URS

Duration of treatment Patients randomized to the interventional arm will receive a SI within 24h after diagnostic URS. In case of multiple diagnostic URS during the follow-up (including 2nd look for incomplete ablation, non-diagnostic first URS or UTUC recurrence) patients randomized to the interventional arm will receive a SI after each diagnostic URS for 2 years after the day of first diagnostic URS.

Follow-up of subjects post discontinuation of study treatment Patients who have discontinued study treatment due to toxicity, symptomatic deterioration, intravesical recurrence or investigator's decision will be followed up for survival until 5 years from the date of diagnostic URS.

Survival All randomized patients, regardless of disease status, will be followed up for survival until 5 years from the date of diagnostic URS.

Investigational product, dosage, and mode of administration Patients randomized to the interventional arm will receive a SI. The chemotherapy will be at investigator's discretion and institutional availability.

The selected chemotherapy must be approved by the MINERVA-CTU in discussion with the local investigator.

Statistical methods This study will randomize 394 patients globally. Patients will be randomized 1:1 to SI or observation.

Randomization will be stratified by the following factors:

1. Center

2. EAU UTUC risk stratification

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 394
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects must meet all the following inclusion criteria to participate in this study:

• Age = 18 years

• Diagnosis primary localized UTUC

• Imaging examinations show no distant metastasis

• Patients who agree to receive SI after URS for UTUC and will undergo the standard treatment, postoperative management, and follow-up in accordance with current guidelines

Exclusion Criteria:

• Any concurrent systemic therapy for any cancer

• Prior bladder cancer within 5 years

• Prior radical cystectomy

• Concomitant bladder cancer

• Bilateral UTUC

• Pregnancy

• Patient refused to participate

• Life expectancy of less than one year

• Solitary kidney

Related Conditions & MeSH terms

• Bladder Cancer
• Carcinoma
• Carcinoma, Transitional Cell
• Urinary Bladder Neoplasms

Intervention

Drug:
• Intravesical Solution
Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna
Austria	Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
David D'Andrea

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of a SI in the prophylaxis of intravesical recurrence after URS for UTUC	Proportion of patients free of intravesical recurrence at 2-years	2 years
Secondary	Time to intravesical recurrence	Time to first occurrence of an bladder tumor after URS for UTUC	5 years
Secondary	5-years intravesical recurrence rates	Proportion of patients free of intravesical recurrence at 5-years	5 years
Secondary	Incidence of high-grade BCa recurrence	Proportion of patients HG with intravesical recurrence at 5 years	5 years
Secondary	Incidence and gravity of adverse events (AEs) due to the SI	Proportion of patients experiencing an AE	2 months
Secondary	Biobanking	To collect and store blood, urine and tissue samples according to each country's local and ethical procedures for identifying candidate markers that may correlate with likelihood of clinical benefit	10 years
Secondary	Genetic mutation analysis	Prevalence of lynch syndrome	3 years
Secondary	To assess disease-related symptoms and HRQoL in patients with UTUC treated with SI compared those undergoing observation		2 years
Secondary	To assess patient-reported treatment tolerability directly using specific PRO-CTCAE symptoms		2 years